Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Theravance |
---|---|
Information provided by: | Theravance |
ClinicalTrials.gov Identifier: | NCT00124020 |
This study (0019) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
Condition | Intervention | Phase |
---|---|---|
Bacterial Pneumonia |
Drug: Telavancin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 0019 |
Study First Received: | July 22, 2005 |
Last Updated: | May 17, 2007 |
ClinicalTrials.gov Identifier: | NCT00124020 |
Health Authority: | United States: Food and Drug Administration |
Bacterial Infections Staphylococcal Infections Gram-Positive Bacterial Infections Methicillin Respiratory Tract Infections |
Respiratory Tract Diseases Lung Diseases Pneumonia, Bacterial Vancomycin Pneumonia |
Anti-Infective Agents Anti-Bacterial Agents Therapeutic Uses Pharmacologic Actions |